诱导化疗后卡培他滨联合同步中度大分割放疗治疗晚期胰腺腺癌
本研究评估诱导化疗后无远处进展的晚期胰腺癌患者接受44.25 Gy/15次大分割放疗联合同步卡培他滨1250 mg/m2/天的可行性、毒性和疗效。254例患者(220例III期,34例IV期)接受治疗,中位随访19个月,III期患者中位总生存19.5个月,1年和2年生存率分别为85.2%和36%。作者结论认为该方案可行、毒性可接受,疗效与标准剂量分割相当。
要点
- 诱导化疗后无远处进展的晚期胰腺癌患者可考虑44.25 Gy/15次大分割放疗联合同步卡培他滨。
- 同步放化疗期间G3胃肠道毒性发生率为3.2%,G3-G4血液学毒性为5.4%。
- III期患者中位OS为19.5个月,1年和2年生存率分别为85.2%和36%。
核心结论
- 作者结论认为,诱导化疗后大分割放疗方案可行,毒性率可接受,疗效与标准剂量分割方案相当。
研究设计与样本
- 本研究为单臂可行性评估研究,纳入诱导化疗后无远处进展的晚期胰腺癌患者。
- 放疗方案为肿瘤及受累淋巴结44.25 Gy/15次,同步卡培他滨1250 mg/m2/天。
- 所有患者评估可行性和毒性,仅III期患者评估OS、PFS、DPFS和LPFS。
- 共254例患者接受治疗,其中III期220例,IV期34例。
主要发现
- 中位随访19个月,诱导化疗中位持续时间6个月。
- 4例(1.6%)未完成放疗(1例早期进展,3例毒性),放疗中位持续时间20天,209例(82%)接受≥75%卡培他滨剂量。
- 同步放化疗期间G3胃肠道毒性发生率为3.2%,G3-G4血液学毒性发生率为5.4%。
- 后续发生G3、G4、G5胃或十二指肠病变者分别为10例(4%)、2例(0.8%)和1例(0.4%)。
- III期患者中位PFS为11.9个月(95%CI:11.4-13),中位LPFS为16个月(95%CI:14.2-17.3),中位DPFS为14.0个月(95%CI:12.6-146.5,原文如此)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To assess feasibility, toxicity and outcome of moderately hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic cancer. MATERIALS AND METHODS: Patients with advanced pancreatic cancer without distant progression after induction chemotherapy (CHT) were considered. Radiochemotherapy (RCT) consisted of 44.25 Gy in 15 fractions to the tumor and involved lymph-nodes concomitant to capecitabine 1250 mg/m2/day. Feasibility and toxicity were evaluated in all pts. Overall survival (OS), progression free survival (PFS), distant PFS (DPFS) and local PFS (LPFS) were assessed only in stage III patients. RESULTS: 254 patients, 220 stage III, 34 stage IV, were treated. Median follow up was 19 months. Induction CHT consisted of Gemcitabine (35 patients), or drug combination (219 patients); median duration was 6 months.Four patients (1.6 %) did not complete RT (1 early progression, 3 toxicity), median duration of RT was 20 days, 209 patients (82 %) received ≥ 75 % of capecitabine dose.During RCT G3 gastrointestinal toxicity occurred in 3.2% of patients, G3-G4 hematologic toxicity in 5.4% of patients. Subsequently, G3, G4, G5 gastric or duodenal lesions occurred in 10 (4%), 2 (0.8%) and 1 patients (0.4%), respectively.Median PFS, LPFS, and DPFS were 11.9 months (95 % CI:11.4-13), 16 months (95 % CI:14.2-17.3) and 14.0 months (95 % CI:12.6-146.5), respectively.Median OS was 19.5 months (95 % CL:18.1-21.3). One- and two-year survival were 85.2 % and 36 %, respectively. CONCLUSIONS: The present schedule of hypofractionated RT after induction CHT is feasible with acceptable toxicity rate and provides an outcome comparable with that achievable with standard doses and fractionation.
引用
- Passoni P, Reni M, Broggi S, et al. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Clin Transl Radiat Oncol. 2024. PMID: 38779525. doi:10.1016/j.ctro.2024.100778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。